London, 28th July 2023 – NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies, today announces the completion of the 15 patient non-small cell lung cancer cohort for the PECan (NCT04436406) Study.
The PECan Study, which commenced in June 2020, has achieved significant milestones, and demonstrated promising results, despite the challenges of conducting imaging trials during the pandemic. The success of this study marks a significant step forward in the development of 99mTc-NM-01 SPECT/CT as a diagnostic agent for measuring PD-L1 expression pre- and post-checkpoint inhibitor therapy making it an excellent non-invasive and holistic imaging treatment prediction and monitoring tool.
The primary objective of the clinical trial was to measure changes in PD-L1 expression using 99mTc-NM-01 SPECT/CT imaging and to correlate these changes with responses to anti-PD-L1 immunotherapy in patients with non-small cell lung cancer (NSCLC). All participants were imaged with 99mTc-NM-01 SPECT/CT prior to treatment and then 9 weeks into treatment.
Prof. Gary Cook, the principal investigator of the trial, expressed his enthusiasm about the findings, stating “We are delighted to have finished PECan study in completing recruitment of a cohort of patients with non-small cell lung cancer and have the opportunity to collaborate with NanoMab Technology Ltd and work with this exciting imaging agent. While full analysis is ongoing and results will be published shortly, early results presented at SNMMI 2022 showed that baseline measurement of PD-L1 expression can predict metabolic response on 18F-FDG PET/CT and that temporal changes in PD-L1 expression during treatment can be monitored”.
Hong Hoi Ting, founder and director of NanoMab said, “The success of the PECan trial confirms that 99mTc-NM-01 SPECT/CT has huge potential of becoming the best companion diagnostic for immune checkpoint inhibitor drugs due to it being non-invasive and providing additional information on the heterogeneity of the tumour microenvironment and thus predicting treatment prognosis”.
The success of this clinical trial would not have been possible without the dedication and commitment of the patients who participated, the healthcare professionals involved, and the unwavering support from our team at NanoMab.
With the positive outcomes from this trial, NanoMab is eager to work with its partners towards making 99mTc-NM-01 SPECT/CT imaging available to patients who may benefit from PD-L1 imaging. NanoMab would like to extend its heartfelt gratitude to everyone who contributed to the success of this clinical trial.
For more information email: info@nano-mab.com
NanoMab Technology Limited is a privately held biopharmaceutical company focusing on cancer precision therapies via the development of radiopharmaceuticals. Our goal is to develop a pipeline of theranostics with our proprietary camelid antibody platform to address the unmet medical need for cancer patients across the world. www.nano-mab.com